Depressed youth, suicidality and antidepressants
Authors: Peter R Mansfield, Melissa K Raven and Jon N Jureidini
Published online: 5 September 2005
Peter R Mansfield,* Melissa K Raven,† Jon N Jureidini‡
* Research Fellow, University of Adelaide, SA; † Lecturer, Flinders University, Adelaide, SA; ‡ Head, Department of Psychological Medicine Women's and Children's Hospital, Adelaide, SA. peter.mansfieldATadelaide.edu.au
To the Editor: Rey and Dudley cite clinical experience as the basis of their recommendation of selective serotonin reuptake inhibitors (SSRIs) — chiefly fluoxetine — for youth with severe depression plus severe impairment or failure of non-drug therapy.1 They do not discuss the evidence on efficacy because they claim that it is “ambiguous enough for scholars to be divided”. It is true that industry-funded scholars are continuing to suggest that SSRIs (chiefly fluoxetine) provide a worthwhile benefit.2 However, the evidence is unambiguous. The four published comparisons of fluoxetine versus placebo for children and adolescents have all been negative on their pre-specified primary endpoints.3,4 A tiny average benefit is likely, but the magnitude of this benefit is unlikely to exceed the magnitude of less frequent but more severe harms. Furthermore, the common clinical impression of worthwhile benefit is to be expected given the large average improvements seen in placebo groups.
Rey and Dudley speculate that psychosocial treatments may be less effective with uncooperative teenagers.1 However, that group may also be at higher risk of the dangers of intermittent use of, and overdosing with, antidepressant drugs.
Rey and Dudley cite Timimi’s critique of the concept of childhood depression5 as supporting “treating depression primarily as a moral or social problem”. However, Timimi did not even allude to depression as a moral problem, and advocated a multi-perspective approach that normalises emotional responses to adverse life experiences and includes interventions addressing biological factors, such as diet, exercise, and cognitive abilities. Rey and Dudley use a related straw-man argument in their final sentence when they suggest that the only alternatives to SSRIs are tricyclic antidepressants, victim blaming, and non-treatment.
Rey and Dudley deny being influenced by the gifts and funding that they have received from drug companies. There is compelling evidence that gifts and funding are effective, on average, for influencing beliefs, especially among people who have an illusion of invulnerability.6 We are not aware of any way that any individual can know that he or she has not been influenced.
Competing interests
References
- Rey JM, Dudley MJ. Depressed youth, suicidality and antidepressants. Med J Aust 2005; 182: 378-379. <eMJA full text>
- March JS, for the TADS Group. Authors of TADS study reply to letter raising concerns. BMJ 2005; 330: 730-731. 0_i1091551
- Jureidini JN, Doecke CJ, Mansfield PR, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879-883. 0_CBBHEJIH
- Jureidini J, Tonkin A, Mansfield PR. TADS study raises concerns. BMJ 2004; 329: 1343-1344. 0_CBBIGGEC
- Timimi S. Rethinking childhood depression. BMJ 2004; 329: 1394-1396. 0_CBBEDCDA
- Katz D, Mansfield P, Goodman R, et al. Psychological aspects of gifts from drug companies. JAMA 2003; 290: 2404-2405. 0_CBBBABEJ
Reorienting Allied Health Into Community-Based Care for People Experiencing Trauma and Social Disadvantage
Simon Rosenbaum, Grace McKeon, Gulsah Kurt, Oscar Lederman, Kemi Wright, Sabuj Kanti Mistry, Jackie E. Curtis, Philip B. Ward, Zachary Steel, Hamish Fibbins, Rachel Morell, Melissa C. Eaton, Andrew Watkins, Ben Harris-Roxas, Brendan Goodger, Eleanor Beck, Megan Teychenne, Joseph Firth, Davy Vancampfort, David Burns, Russell Roberts, Tristan Favaloro, Danielle Weber, Rosanna Barbero, Vasili Maroulis, Melissa Holmes, Stefan Mackenzie, Chiara Mastrogiovanni, Afsana Anwar, Uzma Choudhry, Catherine Sherrington, Jane Currie, Thomas Gadsden, Scott Teasdale
Stigmatising Attitudes Towards People With Depression, Bipolar Disorder, Borderline Personality, ADHD and Early and Long-Term/Untreated Schizophrenia: Representative Survey of Australian Adults
Amy J. Morgan, Anna M. Ross, Gayle McNaught, Rachel Green, Nicola J. Reavley
Psychosocial Hazards for Healthcare Workers: Supporting the Second Victim Also Helps the Primary Victims
Sarah Michael
Supporting Population Mental Health in the Wake of Mass Tragedies
Susan J. Rees, Derrick M. Silove
In the Wake of the National Suicide Prevention Strategy 2025–2035: Suicide Prevention in Type 1 Diabetes
Rigel Paciente, Keely Bebbington, Alix Woolard, Helen Milroy
The risk of death after hospitalisation following intentional self‐poisoning: a retrospective observational study (PAVLOVA‐2)
Firouzeh Noghrehchi, Nicholas A Buckley, Rose Cairns